Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 52
- Registration Number
- NCT02516813
- Locations
- 🇳🇴
Research site, Oslo, Norway
🇩🇪Universitaetsklinikum Schleswig-Holstein - Campus Kiel - Klinik für diagnostische Radiologie, Kiel, Germany
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2020-08-03
- Target Recruit Count
- 792
- Registration Number
- NCT02395172
- Locations
- 🇨🇴
Hemato Oncologos S.A., Cali, Colombia
🇺🇸Healing Hands Oncology and Medical Care, Lawndale, California, United States
🇦🇷Hospital Universitario Austral, Pilar, Argentina
First in Human Study of M4344 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- Drug: M4344 40 mg BIWDrug: M4344 100 mg BIDDrug: M4344 150 mg QDDrug: M4344 350 mg QDDrug: M4344 10 mg BIWDrug: M4344 20 mg BIWDrug: M4344 160 mg BIWDrug: M4344 1200 mg BIWDrug: M4344 700 mg BIWDrug: M4344 80 mg BIWDrug: M4344 1050 mg BIWDrug: M4344 300 mg BIWDrug: M4344 450 mg BIWDrug: M4344 250 mg QDDrug: M4344 400 mgDrug: M4344 500 mgDrug: Carboplatin
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-03-16
- Target Recruit Count
- 97
- Registration Number
- NCT02278250
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
M6620 First in Human Study
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2020-04-01
- Target Recruit Count
- 200
- Registration Number
- NCT02157792
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Long Island Jewish Medical Center - Monter Cancer Center, Lake Success, New York, United States
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 204
- Registration Number
- NCT02155647
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2020-07-13
- Target Recruit Count
- 549
- Registration Number
- NCT01919164
- Locations
- 🇷🇴
Research site, Bucharest, Romania
🇭🇰Research Site, Hong Kong, Hong Kong
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2021-12-20
- Target Recruit Count
- 1756
- Registration Number
- NCT01772004
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc, Encinitas, California, United States
Oral Cladribine in Early Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2021-03-22
- Target Recruit Count
- 617
- Registration Number
- NCT00725985
- Locations
- 🇺🇸
Multiple Sclerosis Center Drive, Neurology Suite 701, Newport Beach, California, United States
🇺🇸MS Center of Brevard MIMA Centry Research Associates, Melbourne, Florida, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
CLARITY Extension Study
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2020-12-07
- Target Recruit Count
- 867
- Registration Number
- NCT00641537
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
🇷🇺Reseach Site, Saratov, Russian Federation
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-10-12
- Target Recruit Count
- 172
- Registration Number
- NCT00436826
- Locations
- 🇪🇸
Research Site, Seville, Spain
🇪🇸Research site, Barcelona, Spain